|
A History of Innovation
CyDex has evolved from a university spin-off developing an advanced drug delivery technology into an emerging specialty pharmaceutical company with product-based revenue streams.
Milestones: |
|
1993 |
CyDex L.C. is founded to commercialize substituted cyclodextrin technologies for drug formulation, developed by scientists at the University of Kansas Higuchi Biosciences Center. |
|
1993 |
CAPTISOL®, which can increase solubility by 10 to 50,000 times, begins development under CyDex licenses from the University and a collaboration with Pfizer Inc. |
|
1996 |
Pfizer becomes CyDex´s first corporate partner, signing a licensing agreement for preclinical and clinical development of certain drug formulations using CAPTISOL. |
|
1996 |
CyDex Inc. incorporates, creating an organizational structure more conducive to the company´s growth. |
|
1998 |
Bristol-Myers Squibb licenses CAPTISOL technology for development of a drug candidate for oncology, becoming CyDex´s second corporate partner. |
|
1999 |
Allergan becomes CyDex´s third corporate partner, licensing CAPTISOL technology for a drug candidate in an ophthalmic formulation. |
|
1999 |
Drug Master File Type V, containing preclinical and clinical safety data for CAPTISOL, is filed with U.S. Food and Drug Administration. |
|
2000 |
Series A financing provides $12 million to support CyDex development of proprietary CAPTISOL-Enabled® drug formulations. |
|
2000 |
Zeldox/Geodon® for Injection (ziprasidone mesylate), a Pfizer therapy for schizophrenia using a CAPTISOL formulation, wins first marketing approval in Europe. |
|
2002 |
Vfend® I.V. (voriconazole), a new antifungal from Pfizer, is cleared for marketing, the first U.S. regulatory approval of a CAPTISOL-Enabled drug. |
|
2002 |
Geodon® for Injection, from Pfizer, wins second U.S. approval of a CAPTISOL-Enabled drug. |
|
2003 |
Management and organizational changes occur with goal of transforming CyDex into a specialty pharmaceutical company. |
|
|
Phase I, human clinical testing is successfully completed for two CyDex developed proprietary products. |
|
2004 |
Series B investment of $17 million from U.S. and European venture capital firms will fund development of a pipeline of promising new products. |
|
2005 |
Vfend® I.V. (voriconazole) is cleared for marketing, the first regulatory approval of a CAPTISOL-Enabled drug in Japan. |
|
2006 |
ABILIFY® Injection (aripiprazole), from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., is the third drug formulation commercially available in the United States utilizing CyDex´s Captisol® enabling technology. |
|
2006 |
CERENIA® Injection (maropitant), a CAPTISOL-Enabled Pfizer formulation used in dogs to prevent vomiting and treat vomiting such as that caused by chemotherapy, received marketing approval throughout the European Union. |
|
|
|
|
|
CAPTISOL and Captisol-Enabled are registered trademarks of CyDex Pharmaceuticals, Inc.
VFEND, ZELDOX/GEODON and CERENIA are registered trademarks of Pfizer Inc.
ABILIFY is a registered trademark of Otsuka Pharmaceutical Co., Ltd.
|
|
|
|
|
|
|
